Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis

Abstract

The Livalo Effectiveness and Safety (LIVES) study was an observational study to examine the efficacy and safety of pitavastatin, a newly developed drug, in approximately 20,000 Japanese patients with hypercholesterolemia. During a 2-year follow-up period, no significant problems concerning safety were observed upon treatment with pitavastatin. Pitavastatin demonstrated potent and stable lowering of the LDL-cholesterol level. The LIVES study subanalyses revealed significant and continuous elevation of HDL-cholesterol in association with pitavastatin treatment and also showed that the drug did not adversely affect glycemic control as evaluated by the glycohemoglobin A_1c level. Moreover, pitavastatin treatment was associated with an increase in estimated glomerular filtration rate in subjects with chronic kidney disease. These results suggest the usefulness of pitavastatin in hypercholesterolemic patients from various backgrounds. The ongoing LIVES study extension is expected to provide further data on cardiovascular outcome in subjects treated with pitavastatin.

Keywords::

• CKD
• efficacy
• eGFR
• HbA_1c
• HDL-C
• LDL-C
• pitavastatin
• safety

Financial & competing interests disclosure

Koutaro Yokote, Hitoshi Shimano, Mitsuyoshi Urashima and Tamio Teramoto have received research grants, honoraria and lecture and consulting fees from Kowa Company, Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Grammatical and linguistic amendments were made, funded by Kowa Pharmaceuticals. They had no further involvement in the article.